

LA JOLLA PHARMACEUTICAL COMPANY
Condensed Consolidated Statements of Operations
(Unaudited)
(in thousands, except per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2019	2018	2019	2018
Revenue				
Net product sales	\$ 5,703	\$ 1,593	\$ 10,098	\$ 2,402
Total revenue	5,703	1,593	10,098	2,402
Operating expenses				
Cost of product sales	551	129	1,051	187
Research and development	22,043	30,867	43,287	59,296
Selling, general and administrative	11,323	22,164	23,643	45,180
Total operating expenses	33,917	53,160	67,981	104,663
Loss from operations	(28,214)	(51,567)	(57,883)	(102,261)
Other (expense) income				
Interest expense	(2,806)	(1,654)	(5,535)	(1,654)
Interest income	604	443	1,317	609
Total other expense, net	(2,202)	(1,211)	(4,218)	(1,045)
Net loss	\$ (30,416)	\$ (52,778)	\$ (62,101)	\$ (103,306)
Net loss per share, basic and diluted	\$ (1.12)	\$ (2.02)	\$ (2.29)	\$ (4.22)
Weighted-average common shares outstanding, basic and diluted	27,108	26,182	27,071	24,462

LA JOLLA PHARMACEUTICAL COMPANY
Condensed Consolidated Balance Sheets
(in thousands, except par value and share amounts)

	June 30, 2019 (Unaudited)	December 31, 2018
ASSETS		
Current assets:		
Cash	\$ 123,446	\$ 172,604
Accounts receivable, net	1,893	1,381
Inventory, net	1,968	2,020
Prepaid expenses and other current assets	5,089	5,111
Total current assets	132,396	181,116
Property and equipment, net	20,430	22,267
Right-of-use lease asset	16,159	—
Restricted cash	909	909
Total assets	\$ 169,894	\$ 204,292
LIABILITIES AND SHAREHOLDERS' (DEFICIT) EQUITY		
Current liabilities:		
Accounts payable	\$ 4,908	\$ 8,572
Accrued expenses	10,347	8,485
Accrued payroll and related expenses	4,080	7,509
Lease liability, current portion	2,646	—
Deferred rent, current portion	—	1,370
Total current liabilities	21,981	25,936
Lease liability, less current portion	27,890	—
Deferred rent, less current portion	—	13,609
Deferred royalty obligation, net	124,351	124,323
Other noncurrent liabilities	8,265	4,503
Total liabilities	182,487	168,371
Shareholders' (deficit) equity:		
Common Stock, \$0.0001 par value; 100,000,000 shares authorized, 27,125,215 and 26,259,254 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively	3	3
Series C-1 ² Convertible Preferred Stock, \$0.0001 par value; 11,000 shares authorized, 3,906 shares issued and outstanding at June 30, 2019 and December 31, 2018; and liquidation preference of \$3,906 at June 30, 2019 and December 31, 2018	3,906	3,906
Series F Convertible Preferred Stock, \$0.0001 par value; 10,000 shares authorized, 0 and 2,737 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively; and liquidation preference of \$0 and \$2,737 at June 30, 2019 and December 31, 2018, respectively	—	2,737
Additional paid-in capital	966,422	950,258
Accumulated deficit	(982,924)	(920,983)
Total shareholders' (deficit) equity	(12,593)	35,921
Total liabilities and shareholders' (deficit) equity	\$ 169,894	\$ 204,292